TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9221964
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha (IFN‐alpha; 3 MU/m2 subcutaneously three times weekly)
Study: 2886534
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose iv mezlocillin (5.0 g)
Study: 2886534
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of iv cefuroxime plus metronidazole
Study: 28616797
Drug: Bimatoprost/timolol maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost/timolol maleate fixed combination (BTFC)
Study: 28616797
Drug: Latanoprost/timolol maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost/timolol maleate fixed combination (LTFC)
Study: 19019932
Drug: Travoprost/timolol maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost/timolol maleate fixed combination (TTFC)
Study: 25008885
Drug: Sildenafil [1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil [1 mg/(kg . d)] three times daily for 7‐10 days
Study: 20569928
Drug: Copper glycinate
Normalized name: copper glycinate
DrugBank: Cupric glycinate (DB11509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper glycinate (2 mg copper/day) for 8 weeks
Study: 16351509
Drug: High-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone soy diet (113-207 mg/day total isoflavones)
Study: 16351509
Drug: Low-isoflavone soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone soy diet (<5 mg/day total isoflavones)
Study: 12351534
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Org 31710
Study: 10078088
Drug: captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril 25 mg three times daily
Study: 1971872
Drug: Gastric delivery
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric delivery system (GDS) for iron supplementation, 50 mg daily
Study: 1971872
Drug: Conventional ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional ferrous sulphate, 50 mg daily
Study: 722473
Drug: Phenobarbital (tranquilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (tranquilizer condition)
Study: 31589645
Drug: Potassium iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium iodide capsule (225 μg iodine) daily for 26 weeks
Study: 31589645
Drug: Iodized salt
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodized salt weekly for 26 weeks
Study: 28925046
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of Hibiscus sabdariffa (AEHS) 250 mg/kg and simvastatin 10 mg/kg
Study: 28925046
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of Hibiscus sabdariffa (AEHS) 500 mg/kg and simvastatin 20 mg/kg
Study: 28925046
Drug: Aqueous beverage
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous beverage of Hibiscus sabdariffa (ABHS) with single-dose simvastatin 40 mg
Study: 26281572
Drug: Fangfeng Tongsheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fangfeng Tongsheng granule (3 g, twice a day for 14 days)
Study: 26281572
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (simulated agent granules, 3 g, twice a day for 14 days)
Study: 21681103
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg transdermal nicotine (TDN) patch
Study: 21681103
Drug: Placebo (drug‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (drug‐free bandage)
Study: 17403842
Drug: Dexamethasone (0.89
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.89 mg/kg over 10 days)
Study: 11507005
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin (AVP) following V(1) receptor blockade
Study: 10987239
Drug: Liposuction (LS)
Normalized name: bisoprolol fumarate Oral Tablet [Emcor LS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposuction (LS) combined with Controlled Compression Therapy (CCT)
Study: 6325044
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg iv)
Study: 29579331
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily
Study: 22157367
Drug: Vinorelbine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 60 mg/m on days 1 and 8 every 3 weeks
Study: 19944151
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10(8)TCID(50) IMVAMUNE dose
Study: 19944151
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three IMVAMUNE doses
Study: 26927900
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulfate
Study: 2152594
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin 200 IU plus calcium 500 mg daily for 2 years
Study: 2152594
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin for 1 year
Study: 2152594
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (19 age-matched women, no treatment)
Study: 2152594
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of calcitonin treatment for 1 year
Study: 27191693
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (15-20 minutes of aerobic exercise plus 40 minutes of resistance exercise), 3 times per week, for 16 weeks.
Study: 21933039
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training
Study: 24354547
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention as part of a National Institute on Drug Abuse‐funded clinical trial of a screening and brief intervention protocol
Study: 21096475
Drug: Robotic rehabilitation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic rehabilitation that delivers movement therapy
Study: 12052800
Drug: Daily elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily elemental zinc (10 mg for infants, 20 mg for older children)
Study: 9180409
Drug: Hydrosystem (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrosystem (topical surfactant)
Study: 6350475
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (ACV)
Study: 28732435
Drug: Oral levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levamisole (50 mg twice a day for two weeks with each vaccination)
Study: 24821457
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid (1,200 mg/day)
Study: 22292370
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine nursing treatment)
Study: 8034816
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (5 group sessions over 8 weeks)
Study: 20051714
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (10(‐5) mol/l)
Study: 20051714
Drug: Substance P
Normalized name: Substance P
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance P (10(‐6) mol/l)
Study: 16109077
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral ascorbic acid 3x/week for 8 weeks (n=10)
Study: 16109077
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg intravenous ascorbic acid 3x/week for 8 weeks (n=11)
Study: 16109077
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral ascorbic acid 3x/week for 3 months (n=70)
Study: 16109077
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=83)
Study: 10425594
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of ondansetron
Study: 10425594
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of dimenhydrinate
Study: 7814759
Drug: Mandibular implant-retained
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandibular implant-retained overdentures
Study: 11837089
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture retained by two IMZ-implants (implant-mucosa-borne)
Study: 11837089
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture on a transmandibular implant (TMI; mainly implant-borne)
Study: 6452987
Drug: Meclocycline sulfosalicylate
Normalized name: Meclocycline Sulfosalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclocycline sulfosalicylate cream, 1 percent, applied twice daily
Study: 6452987
Drug: Meclocycline sulfosalicylate
Normalized name: Meclocycline Sulfosalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclocycline sulfosalicylate cream, 1 percent
Study: 31021451
Drug: Model-free digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-free digital workflow using digital impressions immediately after implant placement
Study: 21118309
Drug: Methotrexate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (initial dose, 15 mg per week)
Study: 21118309
Drug: Cyclosporine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (initial dose, 5 mg per kg of bodyweight per day)
Study: 12082657
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 4,000 to 10,000 IU by subcutaneous injection 3 times weekly
Study: 12082657
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin 50 mg twice daily (Control group)
Study: 10532092
Drug: Letrozole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 0.5 mg once daily
Study: 9681078
Drug: Aminoglutethimide 250
Normalized name: aminoglutethimide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide 250 mg twice daily
Study: 8006395
Drug: Prednisone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.6 to 0.3 mg/kg per day for 1 month) followed by interferon alfa‐2a (3 MU/m2, thrice weekly, for 12 months)
Study: 2456731
Drug: Chlorproguanil with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil with folate supplements
Study: 2456731
Drug: Maloprim with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maloprim with folate supplements
Study: 2456731
Drug: Chlorproguanil without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorproguanil without folate supplements
Study: 29668608
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg (group D1)
Study: 29668608
Drug: Dexmedetomidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.5 μg/kg (group D2)
Study: 29668608
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg/kg (group D3)
Study: 21307769
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine (5, 6, 7, 8, 9, 10, or 11 mg) coadministered with 200 μg morphine and 10 μg fentanyl
Study: 21307769
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine (low doses)
Study: 19190211
Drug: Primaquine 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 0.58 mg/kg/d
Study: 19190211
Drug: Primaquine 0.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 0.83 mg/kg/d
Study: 19190211
Drug: Primaquine 1.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 1.17 mg/kg/d
Study: 16794504
Drug: 6 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine)
Study: 16794504
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of chemotherapy (nitrogen mustard, oncovin, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, dacarbazine) + 2550 cGy involved‐field radiotherapy
Study: 16794504
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and chemoradiotherapy
Study: 11938825
Drug: Shenlong Oral
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenlong Oral Liquid (SLOL) combined with radiotherapy
Study: 9506009
Drug: Investigational transdermal
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational transdermal testosterone systems
Study: 3618133
Drug: Doxycycline treatment
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline treatment preoperatively
Study: 19212170
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative treatment)
Study: 26280823
Drug: Extra Virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra Virgin Olive Oil (EVOO) 50 mL daily for 20 days
Study: 26280823
Drug: Refined Olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined Olive Oil (ROO) 50 mL daily for 20 days
Study: 23766338
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) monotherapy 400/100 mg twice daily
Study: 18672538
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) monotherapy
Study: 23766338
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (zidovudine/lamivudine 300/150 mg twice daily)
Study: 15877670
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (125 mg of ferric gluconate per treatment)
Study: 15877670
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no iron administration)
Study: 15877670
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron and Control
Study: 16606452
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg repaglinide
Study: 31709648
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glipizide
Study: 11678967
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg glibenclamide
Study: 12587769
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs
Study: 3393916
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, bleomycin, and methotrexate/leucovorin (PBM) before local regional treatment
Study: 3393916
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin and infusion 5-fluorouracil
Study: 3393916
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with PBM after surgery and/or radiotherapy
Study: 17325557
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (1.0 g/kg/d amino acids starting within the first day and 1.0 g/kg/d lipid added the next day)
Study: 17325557
Drug: Conventional nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nutrition (10% glucose and electrolytes in the first 72 hours, followed by 0.5 g/kg/d amino acids and lipid)
Study: 14741063
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg intravenously over 30 min)
Study: 11480793
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 600 mg/day
Study: 7826055
Drug: 200-ml milkshake
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-ml milkshake preload
Study: 3046889
Drug: Brand A
Normalized name: Select Brand Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand A levothyroxine sodium tablets
Study: 3046889
Drug: Brand B
Normalized name: Select Brand Bulk-Forming Laxative Powder for Suspension (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand B levothyroxine sodium tablets
Study: 29663458
Drug: Vaccine schedule
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine schedule A (0, 1, and 2 months)
Study: 29663458
Drug: Vaccine schedule
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine schedule B (0, 1, and 6 months)
Study: 29663458
Drug: Vaccine schedule
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine schedule C (0, 1, and 12 months)
Study: 23730838
Drug: 420 mg
Normalized name: choline 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 mg silymarin three times a day
Study: 23730838
Drug: 700 mg
Normalized name: cystine 700 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg silymarin three times a day
Study: 15888560
Drug: Subcutaneous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ghrelin (3.6 nmol/kg)
Study: 10613617
Drug: 2 microg
Normalized name: Beta 2 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 AM
Study: 10613617
Drug: 2 microg
Normalized name: Beta 2 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg 1,25-dihydroxyvitamin D3 administered at 8 PM
Study: 10613617
Drug: Control (pre-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pre-dose measurements)
Study: 7604800
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg once daily
Study: 11018193
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg once daily
Study: 2235230
Drug: Surfactant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (100 mg of phospholipid per kilogram of body weight)
Study: 843188
Drug: Rapid withdrawal
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid withdrawal at a rate of 10% of initial dose per week
Study: 843188
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal at a rate of 3% of initial dose per week
Study: 22590935
Drug: Glucose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose group receiving acetated Ringer's solution containing 1% glucose (n = 10)
Study: 22590935
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving acetated Ringer's solution without glucose (n = 10)
Study: 15876901
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg daily
Study: 15876901
Drug: Buspirone 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 45 mg daily
Study: 15876901
Drug: Methadone taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone taper
Study: 9058493
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (TTS 50, 50 micrograms/die)
Study: 9058493
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE, 0.625 mg/die)
Study: 3017401
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once daily for 5 days
Study: 3017401
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once daily for 10 days
Study: 25454414
Drug: FOLFIRI.3 (irinotecan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) alternating with fixed-dose rate gemcitabine
Study: 25454414
Drug: Fixed-dose rate
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose rate gemcitabine alone
Study: 21415284
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 1200 mg
Study: 19243424
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 400 mg
Study: 18403189
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g eicosapentaenoic acid (EPA) plus 0.3 g docosahexaenoic acid (DHA) per day for 8 weeks
Study: 11239530
Drug: Diane 35
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane 35 (2 mg of cyproterone acetate and 35 microg of ethinyl estradiol)
Study: 11239530
Drug: Diane 35
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane 35 plus finasteride (5 mg daily)
Study: 9895419
Drug: GOS (galacto-oligosaccharides)
Normalized name: Go-dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS (galacto-oligosaccharides) 9 g daily